Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022
- Tuesday, September 6, 2022, 7:14
- Environment
- Add a comment
Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma Two Mini-Oral Presentations on the Pivotal Phase 3 CLEAR and Study 309/KEYNOTE-775…
About the Author
adminasapcorp has written 41302 stories on this site.